BioNTech’s Bold Bet: Can mRNA Therapies for Cancer Offset Declines in Vaccine Sales?
BioNTech is shifting focus from Covid-19 vaccines to innovative cancer treatments, reflecting both promise and risk in biotech. In Q4 2024, earnings per share dropped to €1.08 from €1.90, yet…